{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:32:04Z","timestamp":1793705524033,"version":"4.5.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ijpddr.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T13:54:22Z","timestamp":1560779662000},"page":"148-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles"],"prefix":"10.1016","volume":"11","author":[{"given":"Ariane J.","family":"Sousa-Batista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Pacienza-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria In\u00eas","family":"R\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartira","family":"Rossi-Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2019.06.001_bib1","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib2","first-page":"1","article-title":"A phase II study to evaluate the safety and efficacy of topical 3 % amphotericin B cream ( Anfoleish ) for the treatment of uncomplicated cutaneous leishmaniasis in","volume":"13","author":"Asela","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/39.1.63","article-title":"Evaluation of hypersensitivity to microencapsulated ampicillin in Guinea pigs","volume":"39","author":"Barsoum","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","article-title":"Topical paromomycin with or without gentamicin for cutaneous leishmaniasis","volume":"368","author":"Ben Salah","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib5","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/jac\/dkw012","article-title":"Drug permeation and barrier damage in Leishmania-infected mouse skin","volume":"71","author":"Bocxlaer","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib39","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1016\/j.biomaterials.2011.07.021","article-title":"Accelerated healing of cutaneous leishmaniasis in non-healing BALB\/c mice using water soluble amphotericin B-polymethacrylic acid","volume":"32","author":"Corware","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/asj\/sjy008","article-title":"Treatment session: pooled analysis of Data from the phase 3 REFINE trials","volume":"38","author":"Dayan","year":"2018","journal-title":"Aesthet. Surg. J."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib7","series-title":"DNDi's Strategy for Cutaneous Leishmaniasis [WWW Document]","author":"DNDi","year":"2017"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1365-4632.2012.05460.x","article-title":"Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis","volume":"51","author":"Esfandiarpour","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib9","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S36111","article-title":"The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles","volume":"7","author":"Fr\u00f6hlich","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0300-483X(94)90194-5","article-title":"The mouse ear swelling test (MEST) in the 1990s","volume":"93","author":"Gad","year":"1994","journal-title":"Toxicology"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","article-title":"Nanoparticles for drug delivery: the need for precision in reporting particle size parameters","volume":"69","author":"Gaumet","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4103\/0019-5154.143571","article-title":"Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis","volume":"59","author":"Goyonlo","year":"2014","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib13","first-page":"1","article-title":"Imaging of human cells exposed to an antifungal antibiotic amphotericin B reveals the mechanisms associated with the drug toxicity and cell defence","author":"Grela","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib14","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s11095-009-9841-2","article-title":"Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone \u00ae","volume":"26","author":"Italia","year":"2009","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.det.2015.03.018","article-title":"New world and old world Leishmania infections: a practical review","volume":"33","author":"Kevric","year":"2015","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/jac\/37.3.519","article-title":"Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line","volume":"37","author":"Legrand","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib17","first-page":"80","article-title":"A simple method for quantifying Leishmania in tissues of infected animals. Parasitol","volume":"13","author":"Lima","year":"1997","journal-title":"Today Off."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-13-58","article-title":"Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis","volume":"13","author":"L\u00f3pez","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib19","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0003889","article-title":"A Review: the current in vivo models for the discovery and utility of new anti-leishmanial drugs targeting cutaneous leishmaniasis","volume":"9","author":"Mears","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exppara.2018.02.003","article-title":"Comparing the therapeutic efficacy of different amphotericin B- carrying delivery systems against visceral leishmaniasis","volume":"186","author":"Mendon\u00e7a","year":"2018","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/dth.12377","article-title":"Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis\u202f: a preliminary report","volume":"29","author":"Mushtaq","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4269\/ajtmh.1990.42.43","article-title":"Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs . localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala","volume":"42","author":"Navin","year":"1990","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.intimp.2011.05.014","article-title":"The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response","volume":"11","author":"Nicolete","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0014-5793(02)03714-6","article-title":"CCl4-induced acute liver injury in mice is inhibited by hepatocyte growth factor overexpression but stimulated by NK2 overexpression","volume":"532","author":"Otsuka","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1590\/0074-02760160183","article-title":"Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis\u202f: a retrospective review of a Brazilian referral centre","volume":"111","author":"Silva","year":"2016","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4269\/ajtmh.12-0736","article-title":"Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama","volume":"89","author":"Sosa","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib29","first-page":"1","article-title":"Improved drug loading via spray drying of a chalcone implant for local treatment of cutaneous leishmaniasis","volume":"18","author":"Sousa-Batista","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01822-17","article-title":"Depot subcutaneous injection with chalcone CH8-loaded poly(Lactic-Co-Glycolic Acid) microspheres as a single-dose treatment of cutaneous leishmaniasis","volume":"62","author":"Sousa-Batista","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib31","first-page":"1","article-title":"Chemotherapy of leishmaniasis: present challenges","volume":"20","author":"Uliana","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib32","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/jac\/dky014","article-title":"Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani -infected primary macrophages","volume":"73","author":"Voak","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib33","series-title":"FDA's Regulatory Science Program for Generic PLA\/PLGA - Based Drug Products [WWW Document]. Am. Pharm. Rev","author":"Wang","year":"2016"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00631-18","article-title":"Local skin inflammation in cutaneous leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of liposomal amphotericin B","volume":"62","author":"Wijnant","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpddr.2018.04.001","article-title":"Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome \u00ae and AmBisome \u00ae in murine cutaneous leishmaniasis","volume":"8","author":"Wijnant","year":"2018","journal-title":"IJP Drugs Drug Resist"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib36","doi-asserted-by":"crossref","first-page":"e02009","DOI":"10.1128\/AAC.02009-17","article-title":"AmBisome\u00ae treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy","volume":"62","author":"Wijnant","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.06.001_bib37","first-page":"1","article-title":"In vitro and in vivo evaluations of PLGA microspheres containing nalmefene","volume":"10","author":"Xie","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2019.06.001_bib38","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.41.4.752","article-title":"Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis","volume":"41","author":"Yardley","year":"1997","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320719300193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320719300193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:51:03Z","timestamp":1761922263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320719300193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":39,"alternative-id":["S2211320719300193"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.06.001","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}